Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma

Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma

Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologi...

Full description

Saved in:
Bibliographic Details
Published in:Cancers Vol. 14; no. 19; p. 4617
Main Authors: Parappilly, Michael S, Chin, Yuki, Whalen, Riley M, Anderson, Ashley N, Robinson, Trinity S, Strgar, Luke, Sutton, Thomas L, Conley, Patrick, Klocke, Christopher, Gibbs, Summer L, Chang, Young Hwan, Wu, Guanming, Wong, Melissa H, Skalet, Alison H
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 23-09-2022
MDPI
Subjects:
Antibodies
Antigens
Biomarkers
Biopsy
Cancer
Cancer cells
Development and progression
Disease spread
Eye cancer
Gene expression
Health aspects
Immunocytochemistry
Melanoma
Metastases
Metastasis
Patients
Peripheral blood
Population
Protein expression
Proteins
Tumor cells
Tumors
United States
United States > US
Germany
circulating hybrid cells
cancer biomarker
circulating tumor cells
uveal melanoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared to circulating tumor cells (CTCs). We sought to investigate the potential of CHCs as a prognostic biomarker in uveal melanoma. Methods: We isolated peripheral blood monocular cells from uveal melanoma patients at the time of primary treatment and used antibodies against leukocyte and melanoma markers to identify and enumerate CHCs and CTCs by immunocytochemistry. Results: Using a multi-marker approach to capture the heterogeneous disseminated tumor cell population, detection of CHCs was highly sensitive in uveal melanoma patients regardless of disease stage. CHCs were detected in 100% of stage I-III uveal melanoma patients (entire cohort, n = 68), whereas CTCs were detected in 58.8% of patients. CHCs were detected at levels statically higher than CTCs across all stages (p = 0.05). Moreover, CHC levels, but not CTCs, predicted 3 year progression-free survival (p < 0.03) and overall survival (p < 0.04). Conclusion: CHCs are a novel and promising prognostic biomarker in uveal melanoma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14194617